{"nctId":"NCT00004562","briefTitle":"Occluded Artery Trial (OAT)","startDateStruct":{"date":"1999-09"},"conditions":["Cardiovascular Diseases","Heart Diseases","Myocardial Infarction","Heart Failure, Congestive","Heart Failure"],"count":2201,"armGroups":[{"label":"Optimal Medical Therapy Only (MED)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Beta adrenergic blockers","Drug: Platelet inhibitors","Drug: ACE Inhibitors"]},{"label":"Percutaneous Coronary Intervention (PCI)","type":"EXPERIMENTAL","interventionNames":["Drug: Beta adrenergic blockers","Drug: Platelet inhibitors","Procedure: PTCA and stents","Drug: ACE Inhibitors"]}],"interventions":[{"name":"Beta adrenergic blockers","otherNames":["beta blockers"]},{"name":"Platelet inhibitors","otherNames":["Antiplatelet drugs"]},{"name":"PTCA and stents","otherNames":["Percutaneous Transluminal Coronary Angioplasty","and","Stent Placement"]},{"name":"ACE Inhibitors","otherNames":["angiotensin-converting-enzyme inhibitor"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Recent MI (3-28 days) (Day 1 is the calendar day of the MI system onset)\n* MI is defined based on at least 2 of 3 MI criteria confirmed by: 1) ischemic symptoms ≥30 minutes, 2) cardiac serum marker elevation (creatine kinase (CK) ≥2x upper limit of normal and CK-MB elevated above the upper limit of the laboratory normal) or troponin T, or troponin I elevated at least twice the upper limit of normal, 3) EKG: New Q-waves of ≥0.03 sec and/or 1/3 of QRS complex in ≥2 related EKG leads. If cardiac serum markers are elevated (2), any one of the following EKG findings satisfy inclusion criteria; new ST-T changes (ST elevation or depression), new left bundle-branch block (LBBB), loss of R-wave voltage ≥50% in ≥2 related leads or deep T wave inversions ≥3mm in ≥2 leads.\n* TIMI flow 0 or 1 in infarct related artery (IRA)\n* Meets criteria for high risk: EF \\<50% or site of occlusion is proximal, in left anterior descending (proximal to the second major diagonal branch); large right coronary artery; or circumflex, if supplying large obtuse marginal, and part of inferior wall (i.e., large dominant or co-dominant vessel).\n\nExclusion Criteria:\n\n* Age \\<18 y\n* Clinical indication for revascularization defined as follows: rest or low-threshold angina after MI; severe inducible ischemia on low level exercise or pharmacological stress testing (ST decreased ≥2 mm or inability to complete stage 1 or achieve 3-4 metabolic equivalents without angina, hypotension, or reversible perfusion defects in multiple territories or decreased wall motion thickening in \\>2 segments on echocardiogram); left main coronary disease (≥50% stenosis); or triple-vessel disease (3 major epicardial coronaries with \\>70% stenoses)\n* Serious illness such as cancer or pulmonary disease that limits 3-year survival\n* Severe renal disease defined as serum creatinine \\>3.0 mg/dL that markedly increases risk of radiographic contrast\n* Severe valvular disease\n* History of anaphylaxis to radiographic contrast\n* Infarct artery too small (reference segment diameter \\<2.5 mm), target segment within or beyond extreme tortuosity (\\>90° angulation), or otherwise technically a poor candidate for PCI\n* Chronic occlusion of IRA (seen on angiogram obtained before index MI or angiographic evidence of chronicity, e.g., presence of bridging collaterals)\n* NYHA classes III-IV CHF; patients may be treated for acute heart failure complicating MI and rescreened\n* Cardiogenic shock or sustained hypotension: systolic BP \\<90 mm Hg or cardiac index \\<2.2 L/min per m\\^2\n* LV aneurysm in the same location as index MI and present before index MI\n* Inability to cooperate with the protocol\n* Patient refusal or inability to give informed consent\n* Refusal of patient's physician to allow patient to participate\n* Pregnancy\n* Contraindication to anticoagulation during PCI or to routine antiplatelet therapy after stent implantation\n* Qualifying IRA that has been grafted previously; patients with prior CABG may be enrolled if the IRA was not previously grafted\n* Dilated or hypertrophic cardiomyopathy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Patients That Had a First Occurrence of the Primary End Point (Composite of Death From Any Cause, Nonfatal MI, or Class IV HF)","description":"Number of Patients with Events (death from any cause, nonfatal reinfarction, and hospitalization for New York Heart Association (NYHA) Class IV congestive heart failure). Events were centrally adjudicated.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"230","spread":null},{"groupId":"OG001","value":"219","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Secondary Outcomes (Safety Events)","description":"Number of Participants with Secondary Outcomes (death from any cause, nonfatal MI, class IV HF, cardiac death, occurrence of selected clinical outcomes including stroke, hospitalization for CHF, sustained ventricular tachycardia/ventricular fibrillation, ICD implantation, or the composite end point). Events were centrally adjudicated.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"150","spread":null},{"groupId":"OG001","value":"153","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"212","spread":null},{"groupId":"OG001","value":"199","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null},{"groupId":"OG001","value":"74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"249","spread":null},{"groupId":"OG001","value":"235","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":226,"n":1101},"commonTop":["Nonfatal reinfarction"]}}}